Have a feature idea you'd love to see implemented?
Let us know!
KRYS Krystal Biotech Inc
Price (delayed)
$174.975
Market cap
$5.03B
P/E Ratio
46.41
Dividend/share
N/A
EPS
$3.77
Enterprise value
$4.69B
Krystal Biotech, Inc. is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases.
Highlights
The net income has soared by 175% YoY and by 85% from the previous quarter
The EPS has soared by 169% YoY and by 90% from the previous quarter
The company's quick ratio has shrunk by 54% YoY and by 25% QoQ
Key stats
What are the main financial stats of KRYS
Market
Valuations
Earnings
Shares outstanding
28.73M
Market cap
$5.03B
Enterprise value
$4.69B
Price to earnings (P/E)
46.41
Price to book (P/B)
5.96
Price to sales (P/S)
30.1
EV/EBIT
43.26
EV/EBITDA
40.68
EV/Sales
28.21
Revenue
$166.23M
EBIT
$108.38M
EBITDA
$115.28M
Free cash flow
$77.24M
Per share
Balance sheet
Liquidity
EPS
$3.77
Free cash flow per share
$2.7
Book value per share
$29.37
Revenue per share
$5.81
TBVPS
$32.09
Total assets
$917.66M
Total liabilities
$78.77M
Debt
$7.69M
Equity
$838.89M
Working capital
$610.92M
Debt to equity
0.01
Current ratio
9.5
Quick ratio
9.23
Net debt/EBITDA
-2.93
Margins
Efficiency
Dividend
EBITDA margin
69.3%
Gross margin
93.1%
Net margin
63.7%
Operating margin
-12.6%
Return on assets
12.5%
Return on equity
13.4%
Return on invested capital
24.1%
Return on capital employed
12.8%
Return on sales
65.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KRYS stock price
How has the Krystal Biotech stock price performed over time
Intraday
1.29%
1 week
-1.04%
1 month
-2.5%
1 year
49.49%
YTD
41.04%
QTD
-3.88%
Financial performance
How have Krystal Biotech's revenue and profit performed over time
Revenue
$166.23M
Gross profit
$154.71M
Operating income
-$20.97M
Net income
$105.94M
Gross margin
93.1%
Net margin
63.7%
The net income has soared by 175% YoY and by 85% from the previous quarter
The operating income has soared by 86% YoY and by 69% from the previous quarter
The operating margin has soared by 82% from the previous quarter
The revenue has surged by 73% since the previous quarter
Growth
What is Krystal Biotech's growth rate over time
Valuation
What is Krystal Biotech stock price valuation
P/E
46.41
P/B
5.96
P/S
30.1
EV/EBIT
43.26
EV/EBITDA
40.68
EV/Sales
28.21
The EPS has soared by 169% YoY and by 90% from the previous quarter
KRYS's P/B is 53% above its 5-year quarterly average of 3.9 and 12% above its last 4 quarters average of 5.3
Krystal Biotech's equity has increased by 28% YoY and by 5% QoQ
The P/S is 77% below the last 4 quarters average of 132.7
The revenue has surged by 73% since the previous quarter
Efficiency
How efficient is Krystal Biotech business performance
Krystal Biotech's return on invested capital has surged by 165% YoY and by 71% QoQ
The ROE has soared by 153% YoY and by 74% from the previous quarter
Krystal Biotech's ROA has soared by 152% YoY and by 71% from the previous quarter
The ROS has grown by 6% from the previous quarter
Dividends
What is KRYS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KRYS.
Financial health
How did Krystal Biotech financials performed over time
The total liabilities has soared by 155% YoY and by 46% from the previous quarter
The company's quick ratio has shrunk by 54% YoY and by 25% QoQ
The debt is 99% less than the equity
Krystal Biotech's equity has increased by 28% YoY and by 5% QoQ
The debt has contracted by 10% YoY and by 2.6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.